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Abstract: The aim of this article is to provide a short review of the most relevant   pharmacological 
and clinical data on pramipexole extended release (ER) as well as to address the clinical   utility 
and potential advantages of a once-daily formulation especially in the treatment of early 
  Parkinson’s disease (PD). Pramipexole is widely established as a symptomatic treatment in early 
as well as advanced PD. The development of an ER formulation, with stable pramipexole plasma 
concentration over 24 hours, now offers a bioequivalent once-daily alternative.   Double-blind 
randomized controlled trials in early and advanced PD, have established noninferiority of 
pramipexole ER compared with immediate release as well as superiority of both formulations 
over placebo. The overnight switch from the standard to the once-daily formulation was shown 
to be successful in .80% of patients without requiring any dose adjustments. Potential benefits 
of the prolonged-release design, which have not yet been formally demonstrated in the pivotal 
trial program, include improved compliance and a potential for better symptomatic control, 
particularly in patients with early disease that can be managed with monotherapy.
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Role of dopamine agonists in the treatment  
of Parkinson’s disease
Although levodopa (LD) still remains the gold standard for symptomatic efficacy in 
reducing the motor symptoms of Parkinson’s disease (PD),1 its long-term use is asso-
ciated with the development of potentially disabling motor complications, including 
response oscillations as well as drug-induced dyskinesias (LD-induced dyskinesias), 
affecting approximately 30% of patients after only 2 years of LD exposure.2 The precise 
underlying pathophysiology of LD-induced motor complications is still incompletely 
understood; however, it is believed that pulsatile dopamine-receptor stimulation, leading 
to neuroplastic changes in the basal ganglia circuitry, plays a pivotal role.1,3–5 Dopamine 
agonists (DAs) act directly on striatal dopamine receptors, with preferential effects on 
the D2 over D1 subfamily, and generally have considerably longer half-lives than LD 
(Table 1).6 While the first agents of this class were ergolinic compounds with affinities 
to multiple non-DA-receptor types, the newer agents are nonergolinic and seem to lack 
the risk for cardiovalvular fibrosis, recently reported for ergolinic agonists,7 which have 
since been withdrawn from many markets. In clinical trials involving patients with 
early PD, initial monotherapy with DAs was consistently associated with a significantly 
reduced risk of motor complications compared with LD, over double-blind follow-up 
periods of up to 5 years (Table 2),8–10 such that DAs are currently recommended as 
first-line therapies particularly for patients with younger age at onset.11,12 In addition, Clinical Interventions in Aging 2012:7 submit your manuscript | www.dovepress.com
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DAs are established first-line therapies to reduce motor 
fluctuations in LD-treated patients.11,12 Both types of clini-
cal benefit from DAs are likely to be related to their longer 
half-life, resulting in more continuous striatal DA-receptor 
stimulation. Continuous 24-hour delivery with once-daily 
dosing has become possible with a transdermal formulation 
of the short half-life agonist rotigotine and, recently, novel 
extended-release (ER) formulations have been developed for 
the nonergolinic oral compounds ropinirole and pramipexole. 
The latter principle is likely to increase convenience and pos-
sibly adherence, particularly for patients with early disease 
that can be managed with monotherapy.
Pharmacology and pharmacokinetics 
of pramipexole ER
Pramipexole is a full intrinsic DA with a nonergot structure. 
The aminobenzothiazole compound is highly selective for the 
D2 receptor family and, intragroup, has preferential affinity 
for the D3 receptor subtype.13 The agent lacks affinity for dop-
amine receptors D1 and D5 and displays only little affinity for 
D2 and D4 receptor subtypes.14 Pramipexole ER was designed 
as a prolonged-release tablet with pramipexole dihydrochloride 
monohydrate dispersed homogeneously throughout the matrix. 
The active substance is released proportional to the square-root 
of time15 by two different mechanisms: diffusion and erosion,15 
reaching its maximum plasma concentration (Cmax) approxi-
mately 6 hours after oral administration (immediate release 
[IR]: Cmax 1–3 hours). In other respects the pharmacokinetic 
profile mostly coincides with the well-known IR formulation. 
Following oral administration, the agent shows a bioavailabil-
ity of .90%.15 In fact, pharmacokinetic studies observed an 
increase in Cmax with concomitant intake of a high-fat meal 
(24% after a single dose administration and about 20% after 
multiple dose administrations), but there was no significant 
change in overall area under the curve (AUC0–24 hours).15,16 
  Protein binding is ,20% and the agent is metabolized only to 
a small extent and predominantly eliminated by renal excre-
tion (∼90%). With a renal clearance of approximately 400 mL/
min, the elimination half-life (t½) varies from 8 hours in the 
young to 12 hours in the elderly. Pramipexole ER is available 
in five dosage strengths (0.26 [0.375] mg, 0.52 [0.75] mg, 
1.05 [1.5] mg, 2.1 [3] mg, and 3.15 [4.5] mg [all doses are 
Table I Pharmacological properties of dopamine agonists
D2/D3 
receptor affinity
D1 
receptor affinity
NE 
receptor affinity
5-HT2B 
receptor affinity
Half-life (h)
Ergot agonists
Bromocriptine D2 − + +/− 3–6
Cabergoline D3 . D2 − + + 65
Dihydroergocriptine D2 +/− + + 12–16
Lisuride D2 − + +a 2–3
Pergolide D3 . D2 + + + 15–20
Non-ergot agonists
Apomorphine D3 . D2 + − − 0–5
Piribedil D3 . D2 − +/– − 20
Pramipexole D3 . D2 − +/– − 10
Ropinirole D3 . D2 − − − 6
Rotigotine D3 . D2 + − − 5–7b
Notes: −, no affinity; +, high affinity; +/−, moderate affinity. aAntagonist; bafter transdermal application.
Copyright © 2009, elsevier. Modified with permission from Antonini A, Tolosa e, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in PD.   
Lancet Neurol. 2009;8:929–937.6
Abbreviation: Ne, norepinephrine.
Table 2 Results of the main trials of levodopa versus dopamine agonists in early Parkinson’s disease
Number on LD  
(agonist)
Duration  
(years)
ΔUPDRS part III  
score
Dyskinesia  
(% of patients)
Wearing-off  
(% of patients)
Levodopa Agonist Levodopa Agonist Levodopa Agonist
LD versus ropinirole8 89 (179) 5 −4.8 ± 8.3 −0.8 ± 10.1 45 20 34 23
LD versus pramipexole9 151 (150) 2 −7.3 ± 8.6 −3.4 ± 8.6 30.7 9.9 38.0 23.8
LD versus pergolide10 146 (148) 3 −2.8 ± 7.8   2.8 ± 9.8 26.0 8.2 43.8 30.6
Notes: ΔUPDRS, change in unified Parkinson’s disease rating scale. *Frequency of motor complications (fluctuations plus dyskinesia).
Copyright © 2009, elsevier. Modified with permission from Antonini A, Tolosa e, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in PD. Lancet 
Neurol. 2009;8:929–937.6
Abbreviations: LD, levodopa; UPDRS, unified parkinson’s disease rating scale.Clinical Interventions in Aging 2012:7 submit your manuscript | www.dovepress.com
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expressed in terms of pramipexole base; corresponding dose 
strengths of pramipexole salt are given in brackets]) and is 
approved for use in early PD as well as adjunct therapy in 
advanced PD with motor complications.
Clinical efficacy in early PD
Two large randomized double-blind placebo-controlled 
Phase III trials were conducted to evaluate the clinical 
  efficacy of pramipexole ER in early PD patients.17,18 These 
are summarized as follows.
Two hundred and fifty-nine patients with early PD at Hoehn 
and Yahr stage 1 to 3, diagnosed within the preceding 5 years, 
were randomized (2:2:1) to receive pramipexole ER (0.26–3.15 
[0.375–4.5] mg qd), pramipexole IR (0.088–1.1 [0.125–1.5] mg 
tid), or placebo. Following a 7-week-flexible up-titration phase, 
drug doses were maintained for an additional 26 weeks, during 
which, to maximize patient retention in the trial, open-label 
LD rescue medication was permitted for subjects experienc-
ing insufficient control of parkinsonism. Post-LD-rescue data 
were censored for the primary analysis. At 18 weeks an interim 
analysis on a subset of 253 patients was planned to evaluate 
superiority of efficacy of pramipexole ER to placebo on the 
Unified Parkinson’s Disease Rating Scale (UPDRS) II + III 
(primary endpoint).18 At 33 weeks, the study aimed to demon-
strate noninferiority of pramipexole ER to pramipexole IR in 
the combined score on UPDRS II + III (primary endpoint).17 
Noninferiority was predefined as a treatment-group difference 
for which the lower bound of the 95% confidence interval (CI) 
did not exceed −3 points. This margin had been chosen con-
servatively to be well outside the minimally clinically relevant 
difference on the UPDRS, which has been suggested to be −7 
points for parts II and III combined.19 At 18 weeks, the adjusted 
mean change in UPDRS II + III   combined scores, censoring 
post-LD-rescue data, was −7.4 (1.1) in the pramipexole 
ER group, compared with −2.7 (1.3) in the placebo group 
(P = 0.0010 vs placebo) and −7.5 (1.1) in the pramipexole IR 
group (P = 0.0006 vs placebo).18 Including data from subjects 
receiving LD rescue medication, the adjusted mean change 
was −5.1 (1.3) for placebo, −8.1 (1.1) for pramipexole ER 
(P = 0.0282 vs placebo), and −8.4 (1.1) for pramipexole IR 
(P = 0.0153 vs placebo).18 Hence, using either approach, a 
statistically significant difference between pramipexole groups 
and placebo could be demonstrated from week 4 onward (ER 
P = 0.0111, IR P = 0.0042 vs placebo at week 4 by either 
approach).18 At 33 weeks, UPDRS II + III change – censoring 
post-LD-rescue data – was −8.2 for ER and −8.7 for IR. The 
resultant treatment difference was −0.5 (95% CI: −2.3 to +1.3), 
thereby establishing noninferiority of the ER formulation. 
Including LD-rescue data, the adjusted mean decrease was −8.5 
versus −9.4, revealing a difference of −0.9 (95% CI: −2.7, +0.9), 
which is still well within the predefined margin.17 As already 
demonstrated at 18 weeks, the 33-week analysis confirmed the 
superiority of pramipexole ER over placebo (adjusted mean 
change in UPDRS II + III score: −8.2 ER vs −1.2 placebo 
[P , 0.0001]).17 Consistent with the symptomatic efficacy 
of pramipexole, fewer patients on active treatment required 
LD-rescue medication (7.0% ER, 4.3% IR, 21.4% placebo).17 
Superiority of both pramipexole formulations could also be 
shown for secondary outcome measures, including Global 
Impression of Improvement responder rates (41.4% ER, 45.1% 
IR vs 20.6% placebo [P = 0.0003 and P , 0.0001]), Patient 
Global Impression of Improvement responder rates (34.4% ER, 
32.4% IR vs 16.5% placebo [P = 0.0008 and P = 0.0020]), and 
UPDRS II + III responder rates (66.7% ER, 63.8% IR vs 35.0% 
placebo [P , 0.0001]).17 A summary of the primary and key 
secondary endpoints at week 33 is given in Table 3.
Table 3 Efficacy results at week 33 (FAS/LOCF with levodopa rescue censored)
Placebo 
(n = 103)
Pramipexole ER 
(n = 213)
Pramipexole IR 
(n = 207)
Primary endpoint
UPDRS II + III score, adjusted mean change (95% CI)  
(P versus placebo, ANCOvA)
−1.2 
(−3.1 to 0.6)
−8.2 
(−9.5 to −6.9) 
(,0.0001)
−8.7 
(−10.1 to −7.4) 
(,0.0001)
Key secondary endpoints
CGI-I scale responder rate, % (P versus placebo, CMH)a 20.6 41.4 
(0.0003)
45.1 
(,0.0001)
PGI-I scale responder rate, % (P versus placebo, CMH)b 16.5 34.4 
(0.0008)
32.4 
(0.0020)
Notes: aProportion of patients classified as either much or very much improved; bproportion of patients self-classified as either much or very much better.
Copyright © 2011, wolters Kluwer Health. Modified with permission from Poewe w, Rascol O, Barone P, et al. extended-release pramipexole in early Parkinson disease: 
A 33-week randomized controlled trial. Neurology. 2011;77(8):759–766.17
Abbreviations: FAS, full analysis set; LOCF, last observation carried forward; ER, extended release; IR, immediate release; CMH, Cochran–Mantel–Haenszel test; ANCOVA, 
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Switch study
Rascol et al conducted a randomized, double-blind, double-
dummy, parallel-group study to assess efficacy, safety, and 
tolerability of an overnight switch from pramipexole IR 
to ER in early PD patients.20 After a 2–4-week open-label 
run-in on pramipexole IR tid, 156 patients were switched 
overnight either to ER or to IR at an unchanged daily dos-
age (randomized 2:1). Subjects were allowed a one-step 
dose adjustment as required for efficacy and/or tolerability 
4 and 5 weeks after switching. Dosage levels then had to 
remain stable for another 4 weeks. The primary efficacy 
endpoint was defined as the proportion of patients success-
fully switched (with or without any dosage adjustment) 
at the end of week 9, determined as no worsening from 
baseline UPDRS II + III score .15% and no withdrawal 
due to drug-related adverse events (AEs). Noninferior-
ity was predefined as a 95% CI with a lower bound not 
exceeding −15%. At week 9, 84.5% of patients in the ER 
versus 94.2% in the IR group were considered success-
fully switched (Table 4). The absolute difference between 
groups was −9.76% (95% CI: −18.81%, +1.66%), hence 
noninferiority of pramipexole ER was not formally dem-
onstrated. However, after 9 weeks, 80.6% of ER and 84.6% 
of IR recipients were successfully switched without requir-
ing any dose adjustments. In the ER group, 16.5% had 
increased and 2.9% had decreased their dosage, while   
  corresponding percentages in the IR group were 13.5% 
versus 1.9% (Table 5). The between-group difference for 
increased versus unchanged/decreased dosage was not 
significant (P = 0.6190). The mean pramipexole dosage 
at 9 weeks was 2.75 (±0.95) mg/day (+0.12 mg/day from 
baseline) in the ER, compared with 2.83 (±0.86) mg/day 
(+0.09 mg/day from baseline) in the IR group.
Safety and tolerability
Pooled safety data of the clinical trials in early and advanced 
PD, comprising information from 803 PD patients exposed 
to clinically effective doses of pramipexole ER, show a 
slightly higher rate of AEs for both pramipexole IR and 
ER compared with placebo. However, no significant dif-
ference in AE profiles has been found between the two 
pramipexole formulations. A summary of the most com-
mon side effects is given in Table 6.15 Safety evaluation of 
the 33-week trial in early PD17 also identified somnolence, 
gastrointestinal complaints, and dizziness as the most 
frequent AEs. In this study, a small numerical increase 
in Epworth Sleepiness Scale score was observed in both 
pramipexole groups but mean values remained below the 
cut-off for excessive daytime sleepiness (#10). Impulse 
control disorders were also slightly more common in both 
active treatment groups (four patients in the ER, three in 
the IR, and one in the placebo group). Taken as a whole, 
pramipexole ER showed the same safety and tolerability 
profile as pramipexole IR.
Patient-focused perspectives
Poor compliance has been identified as a major issue in sev-
eral disease areas21–24 including PD.25,26 The irregular intake 
of prescribed medication affects health care on many levels, 
including poor symptom control and reduced quality of life,27 
Table 4 Rates of successful switching after 9 weeks
Time point Successfully  
switched to  
DB ER
Successfully  
switched to  
DB IR
CMH  
P-value,  
ER versus IR
4 weeks 84/103 (81.6%) 48/52 (92.3%) 0.0803
9 weeks 87/103 (84.5%) 49/52 (94.2%) 0.0790
Copyright © 2010, John wiley and Sons. Modified with permission from Rascol O, 
Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching 
from immediate- to once daily extended-release pramipexole in early Parkinson’s 
disease. Mov Disord. 2010;25(14):2326–2332.20
Abbreviations: DB, double blind; ER, extended release; IR, immediate release; 
CMH, Cochran–Mantel–Haenszel test.
Table 5 Dosage change from baseline to 9 weeks
Switched to DB ER Switched to DB IR
Dosage 
increased
Dosage 
unchanged
Dosage 
decreased
Dosage 
increased
Dosage 
unchanged
Dosage 
decreased
entire treatment group 17/103 
(16.5%)
83/103 
(80.6%)
3/103 
(2.9%)
7/52 
(13.5%)
44/52 
(84.6%)
1/52 
(1.9%)
Successfully switched 12/87 
(13.8%)
72/87 
(82.8%)
3/87 
(3.4%)
6/49 
(12.2%)
42/49 
(85.7%)
1/49 
(2.0%)
Not 
successfully switched
5/16 
(31.3%)
11/16 
(68.8%)
0/16 
(0.0%)
1/3 
(33.3%)
2/3 
(66.7%)
0/3 
(0.0%)
Copyright © 2010, John Wiley and Sons. Modified with permission from Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from 
immediate- to once daily extended-release pramipexole in early Parkinson’s disease. Mov Disord. 2010;25(14):2326–2332.20
Abbreviations: DB, double blind; ER, extended release; IR, immediate release.Clinical Interventions in Aging 2012:7 submit your manuscript | www.dovepress.com
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distortion of treatment effectiveness28 as well as increased 
health care expenditure.29,30 The reasons for noncompliance 
are manifold and include fear of side effects, complex drug 
regimens incompatible with everyday life, and dementia. 
In one study, poorer compliance was identified to be more 
likely among younger patients and those with complex drug 
regimens, depression, and lower quality of life.26 Grosset 
et al demonstrated an inverse correlation of compliance and 
drug doses per day in PD patients31 and showed that low 
therapy adherence was significantly associated with poor 
motor scores (UPDRS), more days absent from work, and 
worse mobility (PDQ39).31 In this study, all measures of 
therapy adherence (total number of days adherent, timing 
adherence, and total therapy adherence) were significantly 
higher for once-daily medications, including DAs taken 
once versus three times daily.31 Therefore, the availability of 
once-daily formulations of DAs with established efficacy in 
PD represents an advantage even if there is no added benefit 
of enhanced clinical efficacy or safety. In addition, from the 
patient perspective there is the obvious advantage in terms 
of convenience and ease of use, particularly in early disease 
where monotherapy with a single dose per day is possible. 
Due to blinding purposes, the possible beneficial effects of a 
once-daily formulation on convenience and adherence have 
not been possible to assess in the Phase III trials.17,18,20,32 ER 
formulations of a long-acting DA such as pramipexole may 
also contribute to improved symptom control during the 
night, although this has not been formally studied to date and 
is more relevant to advanced rather than early PD. Further-
more, there is a possibility that the pharmacokinetic profile of 
a slow-release formulation may reduce the risk of peripheral 
dopaminergic side effects such as nausea and vomiting as 
well as central adverse reactions, including somnolence and 
daytime sleepiness, by avoiding rapid plasma level increases 
and high peak concentrations as compared with their IR 
counterparts. This has, however, not been demonstrated in 
the pivotal clinical trials with pramipexole ER.
Conclusion
Pramipexole is widely established as a symptomatic   treatment 
in early as well as advanced PD. The development of an ER 
formulation, with stable pramipexole plasma concentra-
tion over 24 hours, now offers a bioequivalent once-daily 
  alternative. Double-blind randomized controlled trials in 
early as well as advanced PD have established the noninfe-
riority of pramipexole ER compared with IR as well as the 
superiority of both formulations over placebo. The overnight 
switch from the standard to the once-daily formulation was 
shown to be successful in .80% of patients without requiring 
any dose adjustments. Potential benefits of prolonged-release 
once-daily DA formulations include improved compliance 
and a potential for better symptomatic control over the day 
as well as during the night. However, the latter, along with 
reduced risk of dopaminergic side effects, has not been 
formally demonstrated in the pivotal trial program. From a 
patient perspective there is little doubt that once-daily drugs 
offer major advantages in terms of convenience, especially 
for initial monotherapy in early PD.
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